Article PDF
Avoid common mistakes on your manuscript.
References
Cannon CP, Blazing MA, Giugliano RP, et al, 2015 IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 372: 2387–2397.
Murphy SA, Cannon CP, Blazing MA, et al, 2016 Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol 67: 353–361.
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP, 2016 Statins and Type 2 Diabetes Mellitus: An Update After 1 Year. Curr Pharm Des. [Epub ahead of print] PubMed PMID: 26806344.
Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP, 2015 Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? Expert Opin Pharmacother 16: 1449–1461.
Migdalis I, Efthimiadis A, Pappas S, Alexopoulos D, Vlasserou F, Mikhailidis DP, 2009 Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr Med Res Opin 25: 2571–2576.
Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP, 2007 Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 23: 2183–2192.
Acharya T, Huang J, Tringali S, Frei CR, Mortensen EM, Mansi IA, 2016 Statin Use and the Risk of Kidney Disease With Long-Term Foliow-Up (8.4-Year Study). Am J Cardiol 117: 647–655.
Serban MC, Banach M, Mikhailidis DP, 2016 Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Expert Opin Pharmacother 17: 369–380.
Roffi M, Patrono C, Collet JP, et al, 2016 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37: 267–315.
Virani SS, Akeroyd JM, Nambi V, et al, 2015 Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med 128: 1253–1256.
Banach M, Rizzo M, Toth PP, et al, 2015 Statin intolerance — an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 11: 1–23.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Katsiki, N., Athyros, V.G. & Mikhailidis, D.P. More news from IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial). Hormones 15, 5–7 (2016). https://doi.org/10.1007/BF03401397
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03401397